-
Security Type
-
Common Stock
-
Categories
-
Technology, Healthcare & Medical, Financial Services, Education
-
Min Investment
-
$250
-
Location
-
Century City, CA
-
Offering Date
-
December 05, 2019
-
Expected Close Date
-
April 30, 2025
-
Target Raise
-
$50.00K-$5.00M
-
No. Investors
-
181
-
Security Price
-
$1
-
Deal Notes
-
Security Name: Common Stock
$1.00 per share
-
Valuation
-
$51,600,000
- Number of Employees
- 4
- Cash
- $303
- Revenue
- $0
- Short Term Debt
- $1,392,000
- Cost of Goods
- $0
- Long Term Debt
- $8,493
- Net Income
- $-750,289
Company Description
PhorMed is a biopharmaceutical company leading the charge in the field of genomic medicine. We utilize gene therapy to target cancer and mutated cells, allowing the body to begin healing itself, and give new hope to patients suffering from diseases like AML, Hodgkin’s Lymphoma and Parkinson’s, among others.
Perks
Invest >$500, you will receive 5% bonus shares & access to our Investor Club which allows you to vote on drug names, receive special investor updates, and attend Q&A sessions
If you invest >$1,500, you will receive 10% bonus shares & access to our Investor Club.
If you invest >$5,000, you will receive 15% bonus shares & access to our Investor Club.
If you invest >$10,000, you will receive 20% bonus shares, an in-person meeting with the leadership team**, and access to our Investor Club.
*Investors cannot qualify for both bonuses in any single investment. If an investor qualifies for two bonuses the higher of the two bonuses will be applied. All perks occur after the offering is completed.
**Travel Not Included
Key Deal Facts
Current first-line treatment options have severe side-effects and can be toxic
Exciting technology with the potential to treat multiple diseases means expanding opportunities for new markets and the potential for growth
The potential market is $8B+ per year
Use of Proceeds
Research & Development, Marketing, Company Employment, StartEngine Platform Fees
Management Team / Advisory Board Bios
McCoy Moretz M.D.
CEO/Treasurer/Secretary/CMO/Director; Dr. Moretz's primary job is at PhorMed but will continue being surgeon at his own practice, F.A.C.E. of Beverly Hills; Work at PhorMed entails spokes person for all speaking engagements, symposiums and conferences, manage all corporate and clincial directives, assist in protocol design, maintain clincal site communications, assist in expanding clinical sites, and manage all medical related work; 25 hrs/week and will increase as needed.
Prof. Richard L. Chang
Inventor and Scientific Affairs; Writes and publishes new findings, manages all scientific related work, assists writing and appoves all protocol designs, continues the work to better understand the mechanisms of action, and creates all 'methods' for analytical, manufacturing and clinical operations; full time with PhorMed
Isis Luna
Operations Director; Manages all internal operations, human resources, keeps all records and maintains all meeting minutes and filings; full time with PhorMed
Steven J. Davis
Legal Councel; Mr. Davis has his own law practice and primary job at SD Law Group APC; Work at PhorMed entails managing and maintaining all legal, filings, compliance and regulatory matters; 5 hours/week or as needed
Joseph Huffman
Financial Director; Mr. Huffman has his own CPA firm and primary job at Huffman & Huffman, LLC; Work at PhorMed entails maintaining accounting books, A/P, A/R, payroll, taxes, creates financial statements, and files all tax returns; 10hrs/week or as needed
Deal Notes
Security Name: Common Stock
$1.00 per share